Back to search results

PRECISION-BP: Studying Blood Pressure Medication Timing in Obesity

This study, called PRECISION-BP, is looking at how the timing of blood pressure medication affects people with obesity and high blood pressure. Researchers want to see if taking sacubitril-valsartan (49mg-51mg) or valsartan (80mg) in the morning versus the evening can better control blood pressure, especially at night. You might be able to join if you are 18 or older, have a Body Mass Index (BMI) between 30 and 45, and have blood pressure within a specific range (systolic between 130-160mmHg and diastolic between 80-100mmHg). The main goal is to see how much your nighttime systolic blood pressure changes after 28 days of taking the medication. The study's current status is unclear, but it plans to enroll 160 participants.

Study design
This is an interventional study where participants will be randomly assigned to receive one of two medications, either in the morning or evening, for 28 days. It is a double-blind study, meaning neither you nor your doctor will know which treatment you are receiving.
What's involved
You would take a study medication once a day for 28 days. Your blood pressure will be measured at the beginning and after 28 days of treatment.
Compensation
Not stated in the trial record.
Follow-up
Your blood pressure will be measured after 28 days of intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04971720

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Recruiting
PHASE2Ages 18+Interventional
University of Alabama at Birmingham
~160 participants
Updated 2026-04-09 on ClinicalTrials.gov
What's tested:Sacubitril-Valsartan 49 Mg-51 Mg Oral TabletValsartan 80 mg Oral Tablet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in mean nocturnal systolic blood pressure
Measured over At Baseline and after 28 days of intervention.

Conditions

Obesity
Cardiovascular Diseases
Hypertension
Nocturnal Blood Pressure
Natriuretic Peptides
Renin-Angiotensin-Aldosterone System

Explore related trials

HypertensionObesity

Where it's being run

1 sites across 1 states
Alabama1

Study leadership

  • Pankaj Arora, MD, FAHA · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Nehal Vekariya, MS
[email protected]
205-934-7173
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age more than or equal to 18 years of age
Body Mass Index between 30 to 45 kg/m\^2
Blood pressure: Systolic BP more than or equal to 130mmHg and less than or equal to 160mmHg and diastolic blood pressure more than or equal to 80mmHg and less than or equal to 100mmHg. Individuals with hypertension as per the 2017 ACC/AHA Guidelines will be eligible for enrollment

Exclusion

Age less than 18, at screening.
Systolic BP \<130 or \>160mmHg at baseline, or diastolic BP \<80 or \>100 mmHg at baseline
BMI \<30 kg/m\^2 or \>45 kg/m\^2
History of pulmonary hypertension
Have any past or present illness of cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, diabetes, stroke, TIA, or seizure.
Participants who are taking 3 or more classes of hypertension medications on the maximum dose or with resistant hypertension
History of angioedema
Estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73 m2 (CKD-EPI equation); urine albumin creatinine ratio ≥30 mg/g
Hepatic Transaminase (AST and ALT) levels \>3x the upper limit of normal;
Significant psychiatric illness
Anemia (men, Hct \< 38%; women, Hct \<36%)
Participants working night shifts or swing shifts
Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)

What this trial measures

  • Change in mean nocturnal systolic blood pressureAt Baseline and after 28 days of intervention.

    Change in mean nocturnal systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.